Cardiol Therapeutics Inc. (CRDL) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
CRDL currently has 100M outstanding shares. with minimal authorized share overhang for future dilution. The company has significantly diluted shareholders by 47.77% over the past 2 years, indicating aggressive capital raising.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Mar 31, 2026 |
40-F filing | 100.3M shares outstanding |
100M | 0 |
| Mar 31, 2025 |
40-F filing | 82.6M shares outstanding |
83M | 0 |
| Jul 05, 2024 |
F-10 filing: Cardiol Therapeutics Inc. may offer and sell Class A common shares, debt securities, warrants to purchase securities or subscription receipts or any combination of such securities up to an aggregate initial offering price of US $150,000,000. |
65M | 0 |
| Apr 01, 2024 |
20-F filing | 65.4M shares outstanding |
65M | 0 |
| Mar 29, 2023 |
20-F filing | 64.0M shares outstanding |
64M | 0 |
| Jan 26, 2022 |
F-10 filing: Cardiol Therapeutics Inc. files a preliminary short form base shelf prospectus to offer and sell Class A common shares, debt securities, warrants, subscription receipts, or any combination of such securities up to an aggregate initial offering price of US $150,000,000. |
N/A | 0 |
| Jul 08, 2021 |
F-10 filing: Cardiol Therapeutics Inc. files an F-10 for a shelf offering of common shares, debt securities, warrants, subscription receipts, or units up to $100,000,000. |
N/A | 0 |